| Management target | Revenue 17.5% FY27 |
|---|
| Revenue growth | 50% Consolidated YoY; 19% Standalone YoY. |
|---|---|
| Margins | Consolidated margins pressured by Coris R&D and acquisition integration. |
| Order book | EUR 1.41M HAT order for Coris to be supplied Q3. |
| Demand visibility | Strong domestic demand; exports hindered by geopolitical tensions. |
| Management confidence | High in MDx leadership and AMR product growth. |
Growth
Revenue grew 50% YoY; however, PAT fell 29% to ₹8.97 Cr due to Coris consolidation and higher R&D costs.
Outlook
Guided 15-20% overall MDx growth for FY27; Coris expected to grow 10-15% with positive EBITDA.
Risks
Geopolitical tensions affecting export orders; Chinese competition causing 54% de-growth in non-AMR Coris categories.
Investor Presentation filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,576.20
- Market cap
- ₹1,353 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹58.59 Cr
- P/E (TTM)
- 24.4×Sector 37.2×
- Promoter holding
- 40.95%+0.01% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B BlackBio Dx Other Announcement
3B Blackbio Dx Limited has appointed M/s. Sanjay Kasliwal & Associates as the Cost Auditor for the company.
3B BlackBio Dx Q1 FY27 Results: Net Profit ₹9 Cr, Down 28.6% YoY
3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹9 Cr · -28.6% YoY
3B BlackBio Dx Board Meeting Date
3B BlackBio Dx Ltd has scheduled a board meeting for August 13, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.